Baptist Health

Join a highly collaborative, diverse team where your expertise is valued and your career growth is supported. Our Clinical Documentation Improvement specialists enjoy: • Clear career advancement through CDI tiers and DRG Validator opportunities • Strong partnerships with Quality, Case Management, Coding, Physician Groups, and other clinical teams • Supportive, transformational leadership focused on mentorship and development • Exposure to innovative technologies, including AI-assisted tools • A flexible hybrid work model promoting work-life balance • A culture built on teamwork, respect, and meaningful impact Build your career while helping improve patient outcomes and documentation excellence in an environment where you can thrive. Apply today: https://bit.ly/CDI-BHSF EOE, including disability/vets

Lynn Cancer Institute, part of Baptist Health at Boca Raton Regional Hospital, welcomes three physicians whose expertise further expands multidisciplinary cancer care. Together, they bring added depth across breast and gastrointestinal cancer care—from evidence-based systemic therapy to complex minimally invasive surgical treatment—helping patients receive personalized care through every stage of their journey.

Mario Perez, now 70, was living the active life he had maintained for decades as a runner and marathon enthusiast when suddenly severe pain in his back and left leg prevented him from walking. Diagnostic imaging at Baptist Health Herbert Wertheim Cancer Institute revealed extensive cancer involving his spine and pelvis. His diagnosis: stage 4 metastatic prostate cancer. https://lnkd.in/eeNGKQTN

The updated ASTRO clinical practice guideline for pancreatic cancer reflects growing evidence for radiation therapy across the disease spectrum, from resectable and locally advanced to oligometastatic settings. Dr. Michael Chuong, vice chair of the guideline task force, highlights how MR-guided and online adaptive radiotherapy are enabling more comprehensive treatment, including coverage of regions at risk for microscopic disease and dose escalation to gross tumor, with the goal of durable local control for appropriately selected patients. The guideline also identifies key open questions, including how best to integrate radiation with evolving systemic therapies such as RAS inhibitors. American Society for Radiation Oncology (ASTRO)

We’re just days away from the 43rd Annual Echocardiography and Structural Heart Symposium. For those joining us in Miami, here’s a preview of what to expect: practical insights into valve disease, advanced and multimodality imaging, real-world cases, structural interventions and the evolving role of AI in echocardiography. Haven’t registered yet? There’s still time to join cardiologists, cardiac surgeons, imaging specialists and sonographers for two days of clinically relevant education and conversation. Register to attend: https://lnkd.in/e5ahXERJ

What if imaging could show which metastases will respond to treatment, and which need more? Dr. Nikolai Strusberg shared findings at American Society for Radiation Oncology (ASTRO) #ASTRO26 from a lesion-level, AI-driven PSMA PET/CT analysis in patients treated with Lu-PSMA therapy for metastatic castration-resistant prostate cancer. Baseline PET features were associated with how individual lesions responded, supporting quantitative PSMA PET as a potential tool for response-adaptive strategies, including future trials that pair radiopharmaceutical therapy with targeted external beam radiation.

Reirradiation is often limited to palliative doses due to concerns about cumulative toxicity to nearby organs. At American Society for Radiation Oncology (ASTRO) #ASTRO26, Dr. Kathryn Mittauer presented cumulative GI dose findings from our early prospective trial of ablative, 5-fraction MR-guided reirradiation. In 8 of 10 patients, cumulative doses to GI organs at risk exceeded thresholds from the recent ReCOG systematic review, with no grade 3 or higher toxicity observed. Daily on-table adaptive radiotherapy with MR visualization was key to safely escalating dose in this setting.

Proton therapy is increasingly used to treat localized prostate cancer, and long-term data help guide how it's used for different patients. At #ASTRO26, Dr. Marcio Fagundes shares results from his study of 404 patients treated with intensity-modulated proton therapy. With a median follow-up of more than four years, men with intermediate-risk disease had very rare recurrences. Patients with high-and very-high-risk disease had a few more, as expected. Research like this helps refine treatment approaches for men across the full range of localized prostate cancer risk. #RadOnc American Society for Radiation Oncology (ASTRO)

Is leg pain normal or a circulation issue? Not all leg pain is just sore muscles. Sometimes it's a sign of a circulation problem that needs attention. Baptist Health Vascular Surgeon explains how to tell the difference, the warning signs you shouldn't ignore, and what can happen if you do. Watch the full podcast on YouTube.

Radiation therapy is an important tool in treating brain tumors, and managing its potential side effects is part of delivering thoughtful care. At American Society for Radiation Oncology (ASTRO) #ASTRO26 Dr. Rupesh Kotecha, discussed contemporary approaches to diagnosing and managing radiation necrosis. He walked through its four grades, ranging from changes seen only on MRI to cases needing steroids, escalated therapy, or minimally invasive and invasive strategies. His presentation focused on the latest evidence-based strategies to help guide treatment for these patients.